Prognostic value of urokinase-type plasminogen activator in patients with superficial bladder cancer

Urology

Volumn 47, Issue 1, 1996, Pages 34-37

  Hasui, Yoshihiro ^a   Marutsuka, Kousuke ^a   Asada, Yujiro ^a   Osada, Yukio ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

UROKINASE;

ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER INVASION; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; TISSUE LEVEL;

EID: 0030044316     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)80378-1     Document Type: Article

References (25)

1. Soloway MS: Intravesical therapy for bladder cancer. Urol Clin North Am 15: 661-669, 1988.
2. Culter SJ, Heney NM, and Friedell GH: Longitudinal study of patients with bladder cancer: factors associated with disease recurrence and progression, in Bonney WW, and Prout GR Jr (Eds): Bladder Cancer (AUA Monographs). Baltimore, Williams & Wilkins, 1982, pp 35-46.
3. Varkarakis MJ, Gaeta J, Moore RH, and Murphy GP: Superficial bladder tumor: aspects of clinical progression. Urology 4: 414-420, 1974.
4. Catalona WJ: Urothelial tumors of the urinary tract, in Walsh PC, Retik AB, Stamey TA, and Vaugan ED Jr (Eds): Campbell's Urology, 6th ed, Philadelphia, WB Saunders, 1992, pp 1094-1158.
5. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, and Skriver L: Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44: 139-266, 1985.
6. Markus G: The relevance of plasminogen activators to neoplastic growth. A review of recent literature. Enzyme 40: 158-172, 1988.
7. Hisazumi H, Andersson L, and Collins VP: Fibrinolytic activity of in vitro cultivated human bladder cell lines. Urol Res 5: 133-139, 1977.
8. Dubeau L, Jones PA, Rideout WM III, and Laug WE: Differential regulation of plasminogen activators by epidermal growth factor in normal and neoplastic human urothelium. Cancer Res 48: 5552-5556, 1988.
9. See WA: Plasminogen activators: regulators of tumor cell adherence to sites of lower urinary tract surgical trauma. J Urol 150: 1024-1029, 1993.
10. Mitsubayashi S, Akiyama T, Kurita T, Okada K, Bando H, Sasaki T, and Matsuo O: Plasminogen activators in bladder tumors. Urol Res 15: 335-339, 1987.
11. Hasui Y, Marutsuka K, Suzumiya J, Kitada S, Osada Y, and Sumiyoshi A: The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer. Int J Cancer 50: 871-873, 1992.
12. Hasui Y, Marutsuka K, Nishi S, Kitada S, Osada Y, and Sumiyoshi A: The content of urokinase-type plasminogen activator and tumor recurrence in superficial bladder cancer. J Urol 151: 19-20, 1994.
13. Hasui Y, Suzumiya J, Marutsuka K, Sumiyoshi A, Hashida S, and Ishikawa E: Comparative study of plasminogen activators in cancers and normal mucosae of human urinary bladder. Cancer Res 49: 1067-1070, 1989.
14. Bradford MM: A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
15. Kaplan EL, and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
16. Cox DR: Regression models and life tables. J R Stat Soc 34: 187-220, 1972.
17. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennely JJ, and Andreasen P: Urokinase-plasminogen activator, a new independent prognostic marker in breast cancer. Cancer Res 50: 6827-6829, 1990.
18. Foekens JA, Schmitt M, van Putten WLJ, Peters HA, Bontenbal M, Jänicke F, and Klijn GM: Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52: 6101-6105, 1992.
19. Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K, and Blichert-Toft M: High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513-2521, 1993.
20. Malkowicz SB, Nichols P, Lieskovsky G, Boyd SD, Huffman J, and Skinner DG: The role of radical cystectomy in the management of high grade superficial bladder cancer. J Urol 144: 641-645, 1990.
21. Scher HI, Yagoda A, Herr HW, Sternberg CN, Bosl G, Morse MJ, Sogani PC, Watson RC, Dershaw DD, Reuter V, et al: Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. J Urol 139: 470-474, 1988.
22. Weiss RE, Liu BC-S, Ahlering T, Dubeau L, and Droller MJ: Mechanism of human bladder tumor invasion: role of protease cathepsin B. J Urol 144: 798-804, 1990.
23. Pyke C, Græm L, Ralfkiær E, Rønne G, Høyer-Hansen G, Brünner N, and Danø K: The receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res 53: 1911-1915, 1993.
24. O'Brien T, Cranston D, Fuggle S, Bicknell R, and Harris A: Differential angiogenic growth factor expression in superficial bladder cancer. J Urol 155 (suppl): 455A, 1995.
25. Schmetter BS, Habicht KK, Jager RD, Butman BT, Morales A, Lamm DL, and Grossman HB: AuraTek™ FDP: a multicenter trial evaluation of a novel diagnostic method for bladder cancer. J Urol 154 (suppl): 457A, 1995.